Keros Therapeutics (NASDAQ:KROS) Given New $40.00 Price Target at HC Wainwright

Keros Therapeutics (NASDAQ:KROS) had its target price cut by HC Wainwright from $47.00 to $40.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages also recently issued reports on KROS. Wells Fargo & Company increased their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Piper Sandler lowered their target price on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, January 17th. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Truist Financial decreased their price objective on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a report on Monday, December 23rd. Finally, Wedbush downgraded Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Stock Up 0.6 %

Shares of KROS stock opened at $11.01 on Thursday. The firm has a fifty day moving average of $12.64 and a 200-day moving average of $39.79. The firm has a market capitalization of $445.98 million, a price-to-earnings ratio of -2.11 and a beta of 1.39. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Research analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares in the last quarter. KBC Group NV grew its position in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Keros Therapeutics by 6.0% during the fourth quarter. MetLife Investment Management LLC now owns 18,098 shares of the company’s stock worth $286,000 after purchasing an additional 1,027 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Keros Therapeutics by 36.7% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after buying an additional 1,033 shares during the period. Finally, Handelsbanken Fonder AB grew its position in Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock worth $171,000 after buying an additional 1,100 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.